Every Form 4 that Core Scientific, Inc. (CORZ) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CORZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORZ filings page.
Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.
The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific CEO Adam Taylor reported a tax-related share withholding. On 01/23/2026, 274,404 shares of Core Scientific common stock were withheld at a price of $18.79 per share to cover withholding tax obligations tied to the vesting of restricted stock units.
After this automatic withholding, Taylor directly beneficially owned 4,131,300 shares. The transaction is coded "F," indicating it was associated with equity award vesting rather than an open-market sale.
Core Scientific (CORZ) reported an insider transaction on a Form 4. A director purchased 30,000 Tranche 1 Warrants on 11/12/2025, coded “P” for a purchase.
The weighted average purchase price was $9.948 per warrant, with multiple trades in a $9.85–$10.11 range. Each whole warrant is exercisable for one share of common stock at an exercise price of $6.81 per share, subject to adjustments.
The warrants are listed as exercisable beginning 01/23/2024 and expire 01/23/2027. Following the reported transactions, the reporting person beneficially owned 30,000 derivative securities, held directly.
Core Scientific, Inc. (CORZ) director reported a Form 4 purchase. On 11/04/2025, the reporting person bought 5,000 shares of common stock (transaction code P) at $21.50 per share. Following this transaction, the filer beneficially owned 226,687 shares, held as direct ownership.